Medidata announced that it has acquired the digital biomarker business of MC10 to help integrate data from wearable sensors — including clinical-grade metrics — so customers may make clinical trials virtual.
MC10’s offerings will bring novel clinical analytics and biosensor capabilities to Medidata’s existing patient cloud solutions in ePRO (patient-reported outcomes), eCOA (clinical outcome assessments) and biomarker discovery.
Wearable sensors are used in about 15% of studies, and the use of sensors is expected to grow to approximately 70 percent by 2025, according to a 2017 study by Intel. But the physical restrictions placed on patients and clinical sites during the COVID-19 pandemic have interfered with launching some clinical studies and carrying them to completion.
MC10’s focus on clinical-grade data capture and novel digital biomarker development represent an important next chapter — advancing the understanding of disease progression and treatment effect in the home, according to Medidata.
“Medidata is excited to add the pioneering work at MC10 to our ongoing efforts in building a new platform for ingestion and analytics across a wide array of mobile sensors,” said Medidata SVP of mobile health Anthony Costello in a news release. “Incorporating remote biometric data capture and analysis that includes the MC10 nPoint Biostamp, alongside other leading mobile devices, will further strengthen the Medidata platform and help propel the digital transformation of life sciences.”
“Medidata is an exceptional fit for MC10,” added MC10 CEO Ben Schlatka. “Our combined expertise will help customers and partners take a more data-driven approach to bringing targeted therapies to patients. We are looking forward to moving ahead together, accelerating the development and deployment of new innovative offerings for our customers and ultimately transforming therapy development to improve the lives of patients.”
New York-based Medidata is a wholly owned subsidiary of Dassault Systèmes. MC10 is located in Lexington, Mass.
